Burning Rock Receives CE Mark for its OverC™ Multi-Cancer Detection Blood Test Kit

Var Date:2022-05-20

Burning Rock announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities

Burning Rock Receives CE Mark Approval for Three NGS Tumor Kits

Var Date:2022-05-07

Burning Rock announced that the Company had received CE mark approval for three self-developed next generation sequencing (NGS) kits, namely, “OncoScreen™ Plus Cance...

Burning Rock Secures Second NGS Kit Approval from the NMPA

Var Date:2022-03-15

Burning Rock announced that the National Medical Products Administration (NMPA) approved Burning Rock's Human Nine-Gene Mutation Joint Detection Kit (reversible term...

Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx Development Using Burning Rock's OncoCompass Target™

Var Date:2021-11-18

GUANGZHOU, China, Nov. 17, 2021– Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a strategic partnership with Merck KGaA,...

Burning Rock and IMPACT Therapeutics Announce a Global Strategic Partnership for Companion Diagnostics Development

Var Date:2021-08-03

Burning Rock today announced a global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field ...

Burning Rock and Abbisko Therapeutics Announce Strategic Partnership on Co-development of Companion Diagnostics for ABSK091

Var Date:2021-04-29

The two companies will work together to develop a CDx assay for ABSK091 (formerly known as AZD4547) to advance clinical research and development of the drug. The CDx...

Burning Rock Announces an Exclusive in-Licensing of a Risk Stratification Test for Early Stage Lung-Cancer Patients from Oncocyte in China

Var Date:2021-03-02

This agreement will bring DetermaRx™, a risk stratification test for early stage lung cancer patients, to China.

Var Date:2021-03-02

Burning Rock announced that it entered into a development and commercialization agreement with Myriad which will bring myChoice® tumor testing for homologous recombi...

Burning Rock and CStone Pharmaceuticals reached a strategic collaboration on the co-development of companion diagnostics for pralsetinib in China

Var Date:2020-06-29

Burning Rock's close cooperation with CStone is expected to promote the standardization of RET gene testing in China.

Burning Rock deepens cooperation with Illumina to promote development and standardization of NGS-based cancer therapy selection [in China]

Var Date:2020-05-12

Burning Rock and Illumina jointly announced today that they are joining forces to promote the development and standardization of NGS-based cancer therapy selection i...

Burning Rock initiates the first prospective, multi-center pan-cancer early detection study in China

Var Date:2020-05-07

Burning Rock today announces the initiation of its 14,000 patient PREDICT (Pan-CanceR Early DetectIon ProjeCT) study to further develop and validate its pan-cancer e...

Burning Rock Dx Launches Magnis BR to Innovate Total Process Automation for NGS Testing

Var Date:2019-11-18

Exclusively supported by Agilent, this futuristic technology brings NGS testing to more hospitals

Burning Rock announces the completion of the Series C financing of RMB 850 million and strives to build an international leading tumor precision medicine brand

Var Date:2019-08-23

On February 14, 2019, Burning Rock held the signing ceremony and announced the closing of the Series C financing totaling RMB 850 million.

China's first NGS cancer testing kit made by Burning Rock Dx and licensed

Var Date:2019-08-26

On July 23, 2018, National Medical Products Administration (NMPA) vetted and granted a license to Burning Rock Biotech(Guang Zhou) Co., Ltd. for making a creative hi...

Burning Rock Dx Honored with 2018 Guangzhou Hi-tech “Unicorn” and “High-grade, Precision and Advanced” Startup

Var Date:2019-08-25

Burning Rock and other firms were rated as 2018 hi-tech unicorns in Guangzhou. Besides, Burning Rock was also included into the top ten Guangzhou “high-grade, precis...

Burning Rock Dx Certified by the Certification of ISO 13485 Quality Management System

Var Date:2019-08-23

Lately Burning Rock Dx successfully passed certification of the ISO 13485 Quality Management System and received the corresponding certificate for Burning Rock's ent...

Burning Rock and Illumina Collaborate on Molecular Diagnostics for Oncology

Var Date:2019-10-10

August 24, 2015—Burning Rock and Illumina, Inc.(NASDAQ: ILMN) today announced they have entered into an agreement whereby Burning Rock will develop advanced clinical...